hackint0sh/New-Dataset huggingface dataset:
* Getting an early idea if this therapy can help certain aspects of the autoimmune disease, including inflammation in the skin, muscles, and lungs; conditions: Dermatomyositis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: Patients will be enrolled in a sequential manner with respect to the aggressiveness of the conditioning regimen used prior to receiving the CAR T infusion therapy. The first 3 patients will undergo standard conditioning--daily cyclophosphamide (IV, 300 mg/m2) and fludarabine (30 mg/m2) x 3 days. If this regimen is found to allow sufficient engraftment of the CAR T cells, participants will be enrolled in sequential groups (of 3-5) representing milder doses or alternative medications that overall represent gentler cytoreduction, which advancement to each sequential group contingent upon satisfactory number and function of infused CAR T cells. primaryPurpose: TREATMENT masking: NONE count: 21 type: ESTIMATED name: KYV-101 measure: Number of participants experiencing adverse events sex: ALL minimumAge: 25 Years maximumAge: 72 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford University city: Stanford state: California zip: 94305 country: United States lat: 37.42411 lon: -122.16608 hasResults: False
nctId: NCT06297993 id: WIND-PSC-01 briefTitle: Adult Patients With Primary Sclerosing Cholangitis acronym: WIND-PSC overallStatus: RECRUITING date: 2024-04 date: 2029-01 date: 2031-01 date: 2024-03-07 date: 2024-04-09 name: Arbor Research Collaborative for Health class: OTHER briefSummary: Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC. conditions: PSC studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 2000 type: ESTIMATED measure: Develop interventional clinical trial external control using clinical and biomarker data. measure: Identify alternative endpoints to predict clinical benefit using large clinical and biomarker data. measure: Changes in patient reported outcomes over time as assessed by Patient Reported Outcomes surveys. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Schiff Center for Liver Diseases / University of Miami status: RECRUITING city: Miami state: Florida zip: 33136 country: United States name: Cynthia Levy, MD role: CONTACT phone: 306-243-4615 email: clevy@med.miami.edu name: Cynthia Levy, MD role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 hasResults: False
nctId: NCT06297980 id: 23-1513 briefTitle: Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes acronym: MERIT overallStatus: RECRUITING date: 2024-03-15 date: 2026-10-31 date: 2026-10-31 date: 2024-03-07 date: 2024-03-07 name: University of Colorado, Denver class: OTHER name: The Leona M. and Harry B. Helmsley Charitable Trust briefSummary: The objectives of this study are to examine how sex hormones (use of hormonal birth control, menstrual cycle phase) impact glycemic control among women with type 1 diabetes (T1D), and to test adjustments to insulin dosing and food intake to ameliorate cycle-related glycemic variability. A secondary aim is to examine how the menstrual cycle and use of hormonal birth control impact patient-reported outcomes and glycemic responses to physical activity. conditions: Type 1 Diabetes conditions: Hypoglycemia conditions: Hyperglycaemia Due to Type 1 Diabetes Mellitus conditions: Menstruation Disturbances studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This will be a parallel group randomized control trial of a personalized glucose control intervention to target changes in glycemic control related to the menstrual cycle that are identified during a 3 month observational period. primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: Personalized modifications to treatment to address menstrual cycle effects on glycemia measure: Glucose time in range measure: Glucose standard deviation measure: Mean glucose (mg/dL) pre-exercise measure: Mean glucose (mg/dL) while exercising measure: Mean glucose (mg/dL) over 24 hours after exercise measure: Glucose standard deviation measure: Glucose standard deviation sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: University of Colorado status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: JANET K SNELL-BERGEON, PhD role: CONTACT phone: 303-724-6762 email: Janet.Snell-Bergeon@cuanschutz.edu name: Catherine Chartier-Logan, MPH role: CONTACT phone: 3037247505 email: Catherine.Chartier-Logan@cuanschutz.edu name: Sarit Polsky, MD role: SUB_INVESTIGATOR name: Cristy Geno, PhD role: SUB_INVESTIGATOR name: Bryan Bergman, PhD role: SUB_INVESTIGATOR name: Laura Pyle, PhD role: SUB_INVESTIGATOR lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06297967 id: CSAPG-33 briefTitle: Acetic Acid 2% Solution for Skin Ulcers acronym: ECA-AA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-06 date: 2024-03-07 date: 2024-03-12 name: Consorci Sanitari de l'Alt Penedès i Garraf class: OTHER briefSummary: The objective of this clinical trial is to assess the effectiveness of acetic acid in patients suffering from chronic cutaneous ulcers with biofilm. The primary question it seeks to address is whether acetic acid (as a 2% topical solution) is superior to the current standard treatment for chronic cutaneous ulcers with biofilm at our center (Prontosan®).
Participants will be randomly assigned to receive either the acetic acid solution treatment or the standard current treatment. conditions: Ulcer, Skin studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 104 type: ESTIMATED name: Acetic Acid name: Prontosan measure: Change in ulcer area compared to baseline (percentage) at 8 weeks of treatment measure: Percentage of participants with ulcer healing at 4 weeks from the start of treatment. measure: Percentage of participants with ulcer healing at 12 weeks from the start of treatment. measure: Time (days) to ulcer healing from the start of treatment. measure: Changes in the wound bed at 8 weeks according to score of section 6 of the RESVECH2.0 ("Expected Results of the Assessment and Evaluation of Healing of Chronic Wounds" scale. measure: Number of adverse reactions associated with the treatment, collected from the medical record. measure: The healthcare expenditure associated with each branch of the study sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Consorci Sanitari Alt'Pènedes i Garraf city: Barcelona state: Cataluña zip: 08810 country: Spain name: Marta De Vicente role: CONTACT phone: +34 938931616 email: mdevicente@csapg.cat name: Noemí Casaponsa role: CONTACT phone: +34 938960025 phoneExt: 43197 email: recerca@csapg.cat name: Marta De Vicente role: PRINCIPAL_INVESTIGATOR lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06297954 id: GA22-00011 briefTitle: Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding overallStatus: RECRUITING date: 2023-03-16 date: 2024-06 date: 2024-06 date: 2024-03-07 date: 2024-03-07 name: Universidad Autonoma de Nuevo Leon class: OTHER briefSummary: A prospective, randomized, double-blind study will be conducted, including all patients with upper gastrointestinal bleeding, defined as vomiting blood or black bowel movements, within 12 hours prior to admission. Patients will be randomized to receive intravenous metoclopramide 20 mg or placebo, a placebo is a look-alike substance that contains no active drug. Then endoscopy will be performed in the following 120 minutes, evaluating endoscopic visualization with the modified Avgerinos scale. conditions: Upper Gastrointestinal Bleeding studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients will be randomized to receive metoclopramide 20 mg IV or placebo, this randomization will be performed by means of a computer sequence to receive each of the treatment sequences. The sequence of treatment (metoclopramide) and placebo in which they will be distributed to patients will be determined using randomization software. A folio number will be assigned and depending on the sequence the treatment or placebo will be administered. Subsequently, the upper endoscopy will be performed in the following 120 minutes, and the endoscopic visualization will be evaluated by the physician performing the procedure by means of the modified Avgerinos scale primaryPurpose: DIAGNOSTIC masking: DOUBLE maskingDescription: As it is double-blind, both physician and patient will not know the treatment they are receiving and it will only be revealed later at the end of the protocol. Following the previous folios, both the treatment and the placebo will be distributed in boxes by default by the research staff, delivering them to the personnel who will apply the drug or placebo, indicating the doses and frequencies of these when administered. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 50 type: ESTIMATED name: Metoclopramide name: Placebo measure: To determine the usefulness of metoclopramide in improving endoscopic visualisation in patients with upper gastrointestinal bleeding. measure: To determine whether the use of metoclopramide avoids repeating the endoscopic procedure. measure: To determine whether the use of metoclopramide shortens the length of hospital stay. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitario Dr. José Eleuterio González, UANL status: RECRUITING city: Monterrey state: Nuevo León zip: 64460 country: Mexico name: José Luis Herrera Elizondo, Physician role: CONTACT phone: +528180182968 email: here_herrera_11@hotmail.com name: José Alberto González González, Physician role: CONTACT phone: +528183668061 email: jalbertogastro@gmail.com lat: 25.67507 lon: -100.31847 hasResults: False
nctId: NCT06297941 id: REM-422-102 briefTitle: Study of REM-422 in Patients With AML or Higher Risk MDS overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-03-15 date: 2027-06-15 date: 2024-03-07 date: 2024-04-23 name: Remix Therapeutics class: INDUSTRY briefSummary: The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML conditions: Myelodysplastic Syndromes conditions: Higher Risk Myelodysplastic Syndromes conditions: Acute Myeloid Leukemia conditions: Acute Myeloid Leukemia Refractory studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: REM-422 measure: Frequency and severity of Treatment Emergent Adverse Events (TEAEs) measure: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) measure: AML: Rate of Complete Response (remission) (CR) measure: AML: Rate of CR with partial hematologic recovery (CRh) measure: AML: Duration of CR measure: AML: Duration of CRh measure: AML: Overall response rate (ORR) (CR + CRh + CRi + PR) with incomplete hematologic recovery [CRi] + partial response [PR]) per modified IWG response criteria 2003 based on Investigator assessment measure: AML: Duration of response (DOR) measure: MDS: Rate of Compete Response (CR) measure: MDS: Duration of Complete Response (CR) measure: MDS: Overall Response Rate (ORR) measure: MDS: Duration of Response (DOR) measure: Determine pharmacokinetic profile (Cmax) of REM-422 measure: Determine pharmacokinetic profile (Cmin) of REM-422 measure: Determine pharmacokinetic profile (Tmax) of REM-422 measure: Determine pharmacokinetic profile (AUC) of REM-422 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City of Hope city: Duarte state: California zip: 91010 country: United States name: Anthony S Stein, MD role: PRINCIPAL_INVESTIGATOR lat: 34.13945 lon: -117.97729 facility: Memorial Sloan Kettering city: New York state: New York zip: 10065 country: United States name: Eytan M Stein, MD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Courtney D DiNardo, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06297928 id: 2023/11238/I briefTitle: Metabolomics and Bariatric Surgery in Patients With Metabolically Unhealthy Obesity overallStatus: RECRUITING date: 2024-01-01 date: 2025-06-01 date: 2026-12-31 date: 2024-03-07 date: 2024-03-07 name: Parc de Salut Mar class: OTHER briefSummary: The goal of this observational study is to investigate metabolic changes in individuals undergoing bariatric surgery, specifically focusing on those with obesity and varying metabolic health statuses. The main questions it aims to answer are:
Participants will undergo routine evaluations and blood tests before and after bariatric surgery. These tests will include assessments of metabolic health markers and sampling of blood plasma for metabolomic analysis. The study will study changes in metabolic profiles between individuals who transition to metabolically healthy obesity and those who remain metabolically unhealthy after surgery. conditions: Bariatric Surgery Candidate conditions: Obesity, Morbid conditions: Obesity, Metabolically Benign studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 145 type: ESTIMATED name: baratric surgery measure: Identification of Metabolic Signatures Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Analysis Predicting Transition from Metabolically Unhealthy Obesity (MUO) to Metabolically Healthy Obesity (MHO) Status measure: Comparison of Metabolomic Changes Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) between Patients with Persistent Metabolically Unhealthy Obesity (MUO) and Those Transitioning to Metabolically Healthy Obesity (MHO) Status measure: Comparison of Baseline Metabolomic Profile and Its Evolution Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) after Surgery between Patients with Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Hospital del Mar status: RECRUITING city: Barcelona zip: 08003 country: Spain name: David Benaiges Boix, PhD role: CONTACT phone: 0034932483902 email: dbenaiges@psmar.cat name: David Benaiges, PhD role: PRINCIPAL_INVESTIGATOR name: Joan Pedro-Botet, PhD role: SUB_INVESTIGATOR name: Albert Goday, PhD role: SUB_INVESTIGATOR name: Carme Serra role: SUB_INVESTIGATOR name: Elisenda Climent, PhD role: SUB_INVESTIGATOR name: Helena Julià, PhD role: SUB_INVESTIGATOR name: Miguel Olano, MD role: SUB_INVESTIGATOR name: Oscar Pozo, PhD role: SUB_INVESTIGATOR lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06297915 id: 2022/08-45 briefTitle: Infusion Treatments of Chronic Peripheral Neuropathic Pain overallStatus: COMPLETED date: 2022-05-17 date: 2023-05-10 date: 2023-08-01 date: 2024-03-07 date: 2024-03-07 name: Hacettepe University class: OTHER briefSummary: This study aimed to evaluate and compare the efficacy of ketamine and lidocaine infusion in patients with chronic peripheral neuropathic pain.
Patients who received intravenous ketamine infusion and the other patient group who received intravenous lidocaine infusion were evaluated in the study. Pain scores and quality of life were assessed with scales before treatment at two weeks, two months, and six months after treatment. conditions: Neuropathic Pain studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: RETROSPECTIVE count: 102 type: ACTUAL name: Ketamine name: Lidocain measure: Neuropathic Pain Scale measure: Pain Rating Scale measure: Quality of Life Scale sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hacettepe University city: Ankara state: Cankaya zip: 06360 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06297902 id: 2023_31 briefTitle: RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3 acronym: RADPAINT-3 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-06 date: 2030-06 date: 2024-03-07 date: 2024-03-07 name: Oslo University Hospital class: OTHER name: Haukeland University Hospital name: St. Olavs Hospital name: Norwegian University of Life Sciences briefSummary: The objective of the RADPAINT-3 trial is to investigate whether dose painting is safe compared to standard radiotherapy. RADPAINT-3 is a randomized, non-inferiority, multi-center phase II study, initiated at the Section for Head and Neck Cancer, Department of Oncology, Oslo University Hospital, accruing from first half of 2024. The primary endpoint is frequency of grade ≥ 3 (CTCAE v5.0) mucosal ulcers one year after treatment. The expected inclusion period is three years, total study duration is six years and planned inclusion number is 100 patients. The collaborating sites are St Olav´s Hospital and Haukeland University Hospital. The patients will be randomized 1:1 to either standard radiotherapy (2 Gy x 34; total dose 68 Gy) or experimental radiotherapy (dose painting). All patients will have 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission computed tomography (FDG-PET/CT) prior to radiotherapy. In the experimental arm, we will escalate the dose to the hypermetabolic part of the tumor (maximum point dose 83.3 Gy), shown in pre-treatment FDG-PET images. Dose escalation will be applied to these regions during the first half of the fractionated treatment (17 of 34 fractions). The patients in both arms will receive concomitant nimorazole (hypoxic radiosensitizer) and concomitant cisplatin if indicated according to standard treatment. The main inclusion criterion is patients with human-papillomavirus (HPV)-unrelated head and neck cancer with poor prognosis.
If RADPAINT-3 shows that there is no excess toxicity, we will continue the study after a new protocol has been approved. The new primary endpoint will be local control at 1 year after radiotherapy. Power analysis show that we will need in total 182 evaluable patients including the 100 patients from RADPAINT-3. The translational sub-study will then be extended to investigate genetic expression data from pre-therapy routine tumor biopsies and correlate this with the analysis of blood samples and tumor control. conditions: Head and Neck Cancer conditions: Radiotherapy Side Effect studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Dose painting measure: Late mucosal ulcer measure: Early toxicity measure: Late toxicity measure: Odynophagia measure: Health-related quality of life measure: Cytokines sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06297889 id: Ma Hucheng briefTitle: Effect of Core Strength Training on the Physical Fitness and Skills of Youth Field Hockey Players in China overallStatus: RECRUITING date: 2024-02-15 date: 2024-06-01 date: 2024-06-15 date: 2024-03-07 date: 2024-03-08 name: Universiti Putra Malaysia class: OTHER briefSummary: Hockey, tracing its origins back to 2000 BC, has undergone substantial evolutionary transformations throughout the centuries. Initially known by various names, the game transitioned to its modern form approximately 50 years ago, when matches were conducted on grass fields with wooden sticks. In contemporary international hockey, there has been a notable shift towards artificial grass, cultivating a dynamic and fast-paced game that places heightened demands on individual skills, tactical acumen, and physical fitness. This evolution reflects a continuous adaptation, seamlessly blending tradition with cutting-edge equipment and hybrid playing grounds.
To address this research gap, the present study sought to investigate the effects of core strength training on the physical fitness and skill performance of youth hockey players in Gansu Province, China. By doing so, this study not only contributes valuable insights to the existing body of literature but also furnishes theoretical support for the development of hockey sport programs. The findings are anticipated to inform targeted interventions aimed at enhancing athletes' physical fitness and skill performance, ultimately fostering the progression of hockey programs within the sporting landscape of China. conditions: Player studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: In this experiment, the experimental group engaged in the core strength training segment of the intervention specifically devised for this study, whereas the control group underwent conventional strength training activities. primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: core strength training 1-6weeks name: core strength training 7-12weeks measure: Power test measure: Speed test sex: MALE minimumAge: 15 Years maximumAge: 17 Years stdAges: CHILD facility: Ma Hucheng status: RECRUITING city: Lanzhou state: Gansu zip: 730000 country: China name: Hucheng Ma, PHD role: CONTACT phone: +8613909492013 email: 875803848@qq.com name: WEI WEI, Senior Coach role: CONTACT phone: +8618919171585 email: 3371189581@qq.com lat: 36.05701 lon: 103.83987 hasResults: False
nctId: NCT06297876 id: H00023815 briefTitle: COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color overallStatus: RECRUITING date: 2023-05-19 date: 2024-05 date: 2025-05 date: 2024-03-07 date: 2024-03-07 name: University of Massachusetts, Worcester class: OTHER name: Merck Sharp & Dohme LLC briefSummary: Pilot randomized controlled trial testing the investigator's previously developed storytelling method to create an interactive, multi-media storytelling intervention to address community-identified reasons for vaccine hesitancy among Black and Hispanic individuals in Central Massachusetts conditions: Vaccine Hesitancy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: SINGLE maskingDescription: Participants will view either storytelling videos or learn more videos. They will not know which video they will get ahead of time nor will they know that they may get one or the other. whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: Storytelling name: Learn More (Active Comparator) measure: Change in Vaccine Hesitancy measure: Vaccine Uptake sex: ALL minimumAge: 18 Years maximumAge: 105 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Massachusetts Chan Medical School status: RECRUITING city: Worcester state: Massachusetts zip: 01605 country: United States name: Sarah Forrester, PhD role: CONTACT phone: 508-856-8338 email: sarah.forrester@umassmed.edu name: Jeroan Allison, MD role: CONTACT phone: 5088568993 email: jeroanallison@umassed.edu lat: 42.26259 lon: -71.80229 hasResults: False
nctId: NCT06297863 id: DOWN-SUITE briefTitle: Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke acronym: DOWN-SUITE overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2026-09-30 date: 2026-12-31 date: 2024-03-07 date: 2024-03-07 name: University of Milano Bicocca class: OTHER name: Fondazione IRCCS San Gerardo dei Tintori name: Azienda Ospedaliero-Universitaria Careggi, Firenze name: Azienda Ospedaliera Universitaria Gaetano Martino, Messina briefSummary: The DOWN-SUITE study is multicenter, randomised, controlled, open-label clinical trial with blinded outcome assessment comparing collateral status in patients with acute ischemic stroke treated with an in-hospital application of head down tilt -10° to -15° (HDT15) versus usual positioning (0° to +30°) before endovascular mechanical thrombectomy.